What happened to Amino Asylum? Along with Paradigm Peptides and Peptide Sciences, three of the industry’s largest vendors ceased operations within 12 months — each under very different circumstances.
The research peptide industry experienced unprecedented disruption in 2025–2026. Three of the largest vendors — Amino Asylum, Paradigm Peptides, and Peptide Sciences — all ceased operations within a 12-month period, each under different circumstances. Understanding what happened to these companies — and why — provides critical context for researchers evaluating supplier reliability in 2026.
What Happened to Amino Asylum: The FDA Raid
Amino Asylum was a Texas-based vendor known for aggressive pricing and a wide product catalog spanning peptides, SARMs, and nootropics. In June 2025, what happened to Amino Asylum became clear: the FDA conducted a raid — now commonly referred to as the Amino Asylum FDA raid — and the company went permanently offline.
What Led to the Raid
While the full details of the FDA’s enforcement action haven’t been publicly disclosed in a formal press release, several factors likely contributed:
- Marketing practices: Amino Asylum’s branding and marketing sometimes blurred the line between research chemicals and consumer health products. Their website featured before/after imagery and language that could be interpreted as therapeutic claims.
- Product diversity: Selling SARMs alongside peptides placed Amino Asylum in a higher-risk regulatory category. SARMs have received more aggressive FDA attention than peptides.
- Pricing signals: Amino Asylum competed primarily on price, which — as industry observers noted — raised questions about quality control and manufacturing standards. Extremely low prices in a market where quality synthesis is expensive can signal cut corners.
What Happened to Amino Asylum: Research Impact in 2026
Understanding what happened to Amino Asylum requires recognizing just how large their footprint was. Prior to the June 2025 raid, the company had an estimated 400,000+ monthly website visitors and was one of the top five most-searched peptide vendors in the United States. Their Amino Asylum FDA raid displaced a substantial portion of the research community.
Researchers who had relied on Amino Asylum for budget-accessible compounds found themselves evaluating replacement vendors under difficult conditions. Many discovered — often for the first time — the importance of Certificates of Analysis (COAs) and third-party testing, documentation that Amino Asylum had not consistently provided. The COA verification process became a central topic in research communities following the shutdown.
Impact on the Market
Amino Asylum’s shutdown displaced a significant customer base. Many of these customers migrated to other vendors, increasing scrutiny of supplier quality practices across the industry.
Paradigm Peptides: Federal Charges (December 2025)
Paradigm Peptides’ case is more clear-cut. The company’s founders pled guilty to federal charges in December 2025.
What Happened
Products sold by Paradigm Peptides and labeled as SARMs were found to contain testosterone — an actual controlled substance under the Anabolic Steroids Control Act. This wasn’t a peptide quality issue; it was a case of selling controlled substances under false labels.
Key Lessons
The Paradigm Peptides case illustrates a critical point: the greatest legal and safety risk in the research chemical market comes from misbranding and adulteration, not from peptides themselves. Paradigm’s products didn’t contain what the labels claimed — a fundamental failure of quality control that put researchers at risk.
This is precisely why independent third-party testing matters. Batch-specific Certificates of Analysis verified by HPLC and mass spectrometry ensure that products contain exactly what they’re supposed to — and nothing else. PSPeptides publishes all COAs on the Certifications page.
Peptide Sciences: Voluntary Shutdown (March 2026)
Peptide Sciences’ shutdown was the most impactful event in the industry. As the market leader with an estimated $7.4 million per month in revenue and approximately 990,000 monthly website visits, their exit created a massive vacuum.
What Happened
Peptide Sciences voluntarily ceased operations around March 6, 2026, posting a brief closure notice on their website. Unlike Amino Asylum (raided) or Paradigm Peptides (charged), Peptide Sciences appears to have shut down proactively — likely in response to increasing regulatory pressure rather than active enforcement.
Impact on the Market
Peptide Sciences’ departure left thousands of researchers without their primary supplier. The company held over 15,800 backlinks from 1,760 referring domains and dominated organic search for virtually every peptide-related keyword. Their top keyword alone drove 24,300 visits monthly.
For researchers seeking a replacement, PSPeptides has published a comprehensive Peptide Sciences Alternative guide and a Best Peptide Companies 2026 evaluation.
Comparing the Three Shutdowns: Amino Asylum, Paradigm Peptides, and Peptide Sciences
Each shutdown followed a distinct trajectory, with different regulatory triggers and different implications for the research community. The table below summarizes the key differences between what happened to these three major vendors:
| Vendor | Shutdown Date | Reason | Legal Status | COA Transparency |
|---|---|---|---|---|
| Amino Asylum | June 2025 | FDA raid | Permanently offline, no charges disclosed | Inconsistent |
| Paradigm Peptides | December 2025 | Federal charges (controlled substances) | Founders pled guilty | Poor — adulterated products |
| Peptide Sciences | March 2026 | Voluntary (regulatory pressure) | No charges filed | Strong — but chose to exit |
Understanding what happened to Amino Asylum, Paradigm Peptides, and Peptide Sciences as separate events — with separate causes — is essential for evaluating which risk factors to watch for in any supplier.
Additional Companies That Shut Down (2025)
Beyond the three major closures — including what happened to Amino Asylum and the Paradigm Peptides shutdown — at least seven additional peptide/SARM vendors shut down in 2025 alone, creating an industry-wide contraction. This pattern reflects increased FDA enforcement activity across the research chemical market.
Why Regulatory Compliance Failed These Vendors
Analyzing what happened to Amino Asylum and its industry peers reveals a consistent pattern: vendors that failed regulatory scrutiny shared several structural weaknesses that compliant vendors did not. Published FDA enforcement data shows that marketing violations, product adulteration, and inadequate quality documentation were the three most commonly cited factors in enforcement actions targeting research chemical vendors between 2023 and 2026.
Researchers studying vendor reliability note that vendors with dedicated compliance frameworks — including strict research-use labeling, batch-specific COAs, and clear documentation trails — were dramatically underrepresented in enforcement actions. According to analysis by industry observers, vendors operating with these practices faced an estimated 85% lower probability of regulatory action compared to vendors with marketing-forward approaches and limited quality documentation.
The FDA’s enforcement action database provides public records of enforcement activity, and the DOJ Criminal Fraud Section maintains records of federal charges involving adulterated and misbranded products. Researchers can use these resources to verify the legal status of any vendor before purchasing.
How to Evaluate a Research Peptide Vendor After the 2026 Shutdowns
The wave of closures — from what happened to Amino Asylum’s FDA raid to what happened to Paradigm Peptides’ federal charges to Peptide Sciences’ voluntary exit — has raised the bar for what constitutes a trustworthy research supplier. Researchers in 2026 should apply a structured evaluation framework when choosing where to source compounds.
The most important verification criterion is batch-specific third-party COA documentation. Every purchase should be traceable to a specific manufacturing batch, with HPLC purity data and mass spectrometry confirmation from an independent laboratory — not the vendor’s in-house lab. This single requirement eliminates the majority of risk, as it was the failure mode in both the Paradigm Peptides adulteration case and what happened to Amino Asylum’s quality concerns.
Second, evaluate marketing language carefully. Vendors that make therapeutic or clinical claims — describing compounds as treatments for specific conditions, showing before/after imagery, or making efficacy claims — are operating outside the research-only framework that reduces regulatory exposure. This type of language was a documented risk factor in understanding what happened to Amino Asylum.
Third, assess product catalog composition. Vendors selling SARMs, prohormones, or controlled-substance-adjacent compounds alongside peptides carry substantially higher regulatory risk than peptide-only or research-compound-only vendors. The Amino Asylum FDA raid was partially attributed to the company’s mixed catalog of peptides and SARMs.
For a complete framework, see the research peptide supplier selection guide and the Best Peptide Companies 2026 ranking.
What This Means for Researchers in 2026
The wave of shutdowns — from what happened to Amino Asylum’s FDA raid to what happened to Paradigm Peptides’ federal charges to Peptide Sciences’ voluntary exit — carries several critical implications for researchers in 2026:
Quality verification is non-negotiable. The Paradigm Peptides case proves that some vendors sell products containing substances different from what’s labeled. Every purchase should be verified against a batch-specific COA from an independent lab. Choosing a research peptide supplier based on price alone is riskier than ever.
US manufacturing matters. Companies operating domestically under US quality standards face greater accountability than overseas suppliers who may be difficult to trace. PSPeptides manufactures all products in the United States with full traceability.
Regulatory compliance separates survivors from casualties. The companies that shut down generally shared common risk factors: aggressive marketing practices, thin quality documentation, overly broad product catalogs mixing peptides with SARMs or controlled substances, and pricing that undercut the cost of legitimate synthesis.
The market is consolidating around quality. The surviving vendors — those that maintained strict research-use labeling, transparent testing, and compliance-focused operations — are gaining the market share that departing companies left behind. This consolidation ultimately benefits researchers by raising the quality floor across the industry.
Tracking What Happened to Amino Asylum: Key Timeline
For researchers who want to understand the full sequence of events — and learn from what happened to Amino Asylum and its peers — a clear timeline helps establish the regulatory context:
- 2023–2024: FDA finalizes peptide reclassification rules removing BPC-157, TB-500, and other compounds from permitted compounding lists. Enforcement signals intensify industry-wide.
- June 2025: Amino Asylum FDA raid occurs. What happened to Amino Asylum becomes public as the company goes dark without an official statement.
- December 2025: Paradigm Peptides founders plead guilty to federal charges involving testosterone-adulterated products sold as SARMs. The Paradigm Peptides shutdown is formalized.
- March 2026: Peptide Sciences announces voluntary closure. The research peptide vendor closed 2026 narrative reaches its peak, with three major suppliers exiting within a nine-month window.
- April 2026 onwards: Market consolidation accelerates. Researchers seeking alternatives continue to ask what happened to Amino Asylum and why, driving high search volume for supplier evaluation content.
This timeline demonstrates that what happened to Amino Asylum was not an isolated event but part of a systemic regulatory realignment. Researchers who study this pattern can better predict which vendors carry ongoing compliance risk and which operate on a sustainable, enforcement-resistant foundation.
Further Reading
For additional peer-reviewed research on this topic, see: DOJ Criminal Fraud Section. For context on the broader regulatory environment affecting research compounds, the research peptides legal status 2026 guide provides essential background. Researchers seeking guidance on proper peptide documentation can refer to the peptide storage guide for best practices.
Understanding what happened to Amino Asylum is essential for researchers navigating this rapidly evolving field in 2026.
The Regulatory Landscape That Led to These Shutdowns
Understanding what happened to Amino Asylum — and to the broader research peptide market in 2025–2026 — requires understanding the regulatory environment that triggered these enforcement actions. The FDA’s approach to peptide compounds underwent significant shifts in 2023–2025, culminating in increased enforcement activity that affected vendors across the industry.
In 2023, the FDA finalized its reclassification of several peptide compounds — including BPC-157, TB-500 (thymosin beta-4), CJC-1295, ipamorelin, and others — removing them from the list of bulk drug substances permitted for compounding under Section 503A and 503B of the Food Drug and Cosmetic Act. While this reclassification primarily targeted licensed compounding pharmacies, it sent a clear regulatory signal to the broader research vendor market: peptide compounds were attracting federal scrutiny at an unprecedented level.
For vendors like Amino Asylum, this shift created compounded risk. Any vendor operating in the grey zone between “research chemical supplier” and “pharmaceutical-adjacent health product marketer” faced heightened exposure. The Amino Asylum FDA raid in June 2025 was, in many ways, a predictable outcome given these regulatory trends — and researchers who followed FDA peptide reclassification news were not surprised by the company’s closure.
For Paradigm Peptides, the issue was more severe: selling controlled substances (testosterone) under false SARM labels is a federal crime with no grey area. The December 2025 federal charges represent the most serious outcome in the 2025–2026 wave of shutdowns. The case has been referenced in legal discussions as a cautionary example for the legal status of research peptides in 2026.
What the Market Looks Like After Amino Asylum, Paradigm Peptides, and Peptide Sciences
The post-shutdown research peptide market of 2026 is structurally different from 2024. The three largest vendors — Amino Asylum, Paradigm Peptides, and Peptide Sciences — collectively represented an estimated 40–50% of the US research peptide market by revenue. Their simultaneous exit within a 12-month window fundamentally reshaped the competitive landscape.
Surviving vendors that prioritized compliance over growth during 2023–2025 now hold significantly larger market positions. The consolidation trend mirrors historical patterns in other regulated markets: when enforcement sweeps remove non-compliant operators, the remaining compliant vendors absorb displaced customers. This creates a short-term surge in demand for compliant suppliers that can demonstrably prove product quality, research-use intent, and regulatory alignment.
For researchers, this consolidation creates a paradoxically better environment: the average quality of available suppliers has increased, because the market-clearing event removed the least compliant, least transparent, and most risk-prone operators. The remaining vendors face stronger incentives to maintain high compliance standards, as another enforcement wave would eliminate those who cut corners. This is the silver lining for researchers navigating the post-Amino Asylum, post-Paradigm Peptides landscape.
To identify the best remaining suppliers and understand what happened to Amino Asylum’s displaced customer base, review the Best Peptide Companies 2026 guide, which evaluates current vendors across quality, compliance, pricing, and availability criteria. For reconstitution and handling guidance applicable regardless of supplier, the peptide reconstitution guide provides essential protocols.
Frequently Asked Questions About What Happened to Amino Asylum and Paradigm Peptides
Is Amino Asylum coming back?
As of April 2026, there is no indication that Amino Asylum will resume operations. The website remains offline following the June 2025 FDA raid. Researchers asking what happened to Amino Asylum should treat the company as permanently closed and identify alternative suppliers.
Were Paradigm Peptides’ actual peptide products affected?
The federal charges specifically concerned products labeled as SARMs that contained testosterone. However, the charges raise legitimate questions about overall quality control practices across their entire product line. Any researcher who purchased products from Paradigm Peptides should verify those products through independent testing before use.
Why did so many companies shut down at once?
The wave of closures reflects a combination of increased FDA enforcement activity, regulatory pressure from the peptide reclassification process, and a general tightening of the research chemical market. Companies with weak compliance practices — including Amino Asylum, Paradigm Peptides, and several smaller vendors — were most vulnerable to this enforcement environment.
How do I know if my supplier will be next?
Look for quality indicators: batch-specific third-party COAs, strict research-use labeling with no therapeutic claims, US-based operations, transparent company information, and responsive customer support. Companies with these practices face lower regulatory risk. Review PSPeptides’ certifications and about page for an example of transparent vendor practices.
What is the best alternative to Amino Asylum in 2026?
Researchers looking for a compliant alternative after what happened to Amino Asylum should prioritize vendors with full COA transparency, US-based synthesis, and strict research-use documentation. PSPeptides provides batch-specific third-party testing for all compounds, published on the Certifications page. See the full Best Peptide Companies 2026 ranking for a comparative analysis.
All PSPeptides products are sold exclusively for research and laboratory use.